KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)DivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Edwards Lifesciences (EW) Depreciation & Amortization (CF) (2016 - 2025)

Edwards Lifesciences (EW) has 17 years of Depreciation & Amortization (CF) data on record, last reported at $42.7 million in Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) changed 0.23% year-over-year to $42.7 million; the TTM value through Dec 2025 reached $156.6 million, up 0.9%, while the annual FY2025 figure was $156.6 million, 0.9% up from the prior year.
  • Depreciation & Amortization (CF) reached $42.7 million in Q4 2025 per EW's latest filing, up from $39.2 million in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $42.7 million in Q4 2025 and bottomed at $32.4 million in Q1 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $36.6 million, with a median of $35.9 million recorded in 2021.
  • Peak YoY movement for Depreciation & Amortization (CF): skyrocketed 46.12% in 2021, then fell 6.5% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $33.0 million in 2021, then rose by 7.27% to $35.4 million in 2022, then rose by 3.67% to $36.7 million in 2023, then rose by 16.08% to $42.6 million in 2024, then grew by 0.23% to $42.7 million in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $42.7 million in Q4 2025, $39.2 million in Q3 2025, and $38.1 million in Q2 2025.